Sat.Aug 20, 2022 - Fri.Aug 26, 2022

article thumbnail

Inflation Reduction Act Benefits Medicare Patients

Drug Topics

Medicare users will see prescription drug pricing reform thanks to the Inflation Reduction Act.

469
469
article thumbnail

Patents, pandemics and pricing: a peek at the top drug from every big pharma

PharmaVoice

A look at how the biggest pharma companies in the world and their top-selling drugs fared in the first half of the year.

278
278
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Study: Myocarditis Risk Is Significantly Higher After COVID-19 Infection Vs After Vaccine

Pharmacy Times

Analysis includes nearly 43 million individuals aged 13 year and older who received at least 1 dose in England between December 1, 2020, and December 15, 2021.

Vaccines 179
article thumbnail

Making coupons count for patients at the pharmacy counter

PhRMA

Too many patients face high out-of-pocket costs for brand medicines, even when they have insurance.

Insurance 147
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Leukemia Patients Turn to Online Pharmacies Due to Escape High Drug Prices

Drug Topics

Researchers report that half of the online pharmacies are rogue operations that may operate without a license or have other serious shortcomings.

469
469
article thumbnail

The story behind the PharmaVoice 100

PharmaVoice

Taren Grom, our editor-in-chief emeritus, explains how the coveted PharmaVoice 100 awards got its start and what makes it stand out in the industry.

264
264

More Trending

article thumbnail

Blister material as a source of nitrosamine impurities

European Pharmaceutical Review

Following numerous recalls, the industry is striving to investigate the causes, sources and ways to mitigate carcinogenic nitrosamine impurities. In a recent paper, published in the International Journal of Pharmaceutics , researchers identified nitrocellulose blister packaging as a potential source of N -nitrosodimethylamine (NDMA) and N -nitrosodiethylamine (NDEA) impurities.

Packaging 143
article thumbnail

COVID-19: An Attack on the Brain

Drug Topics

What are the long term psychiatric and neuropsychiatric complications of COVID-19?

468
468
article thumbnail

With market success at stake, can tech help solve the diversity problem in clinical trials?

PharmaVoice

Diversity in clinical trials isn’t only important for the health of the overall patient population — it can save millions in lost profits.

264
264
article thumbnail

Pharmacists and Deprescribing in a Palliative Care Setting

Pharmacy Times

As pharmacists take on new responsibilities, researchers have been studying the effects of pharmacists on interprofessional care teams.

158
158
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Long COVID but short on treatment options

pharmaphorum

With COVID-19 vaccines and therapeutics developed in rapid time, Ben Hargreaves investigates why this has not been the case with the creation of a treatment for Long COVID. The condition is more common than might be thought and presents a significant burden to patients, and yet the pipeline of potential therapies remains relatively sparse. When the pandemic first struck, the gravity of the situation did not take long to set in.

Vaccines 134
article thumbnail

Inflammatory Bowel Disease Treatment Costs Reduced with IFX biosimilar

Drug Topics

Although further studies are needed to confirm the long-term effects, recent studies have shown the infliximab biosimilar to be a safe, effective, and cost reducing treatment for inflammatory bowel diseases.

460
460
article thumbnail

Overcoming mental health’s drug development challenges with AI

PharmaVoice

PsychoGenics is leveraging AI-driven drug discovery platforms to advance mental health treatments for schizophrenia, bipolar disorder and treatment-resistant depression.

263
263
article thumbnail

78% of Retail Pharmacists Fear Losing Patients When They Choose New Medicare Plans

Pharmacy Times

Additionally, approximately 70% who responded to the EnlivenHealth survey say that one-third or more of their revenue comes from individuals eligible for the government health insurance.

Insurance 139
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Frazier PhRMA Scholarship awarded to four college-bound students in Philadelphia and DC

PhRMA

The Kenneth C. Frazier PhRMA Scholars Program is going strong in 2022—and we are expanding our horizons to a new city. This summer, we are thrilled to announce four new recipients: Arianna Camacho-Mendez and Axel Orellana from Washington, D.C.; and Michelle Tanujaya and Jackie Zhao, our first students from Philadelphia. Congratulations to these amazing scholars!

130
130
article thumbnail

Plaque Psoriasis Treatment Gets Even More Company

Drug Topics

Nonsteroidal topical agents and TYK2 inhibitors may join an already full armamentarium.

281
281
article thumbnail

First 90 Days: Agios Pharmaceuticals’ Brian Goff

PharmaVoice

The rare disease veteran and first-time CEO is bringing his expertise to the company as it launches the first FDA-approved treatment for pyruvate kinase (PK) deficiency.

FDA 246
article thumbnail

Foot Care Is Essential for Patients With Diabetes

Pharmacy Times

With proper knowledge, they can complete self-examinations and be adherent to clinical exams.

139
139
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

A List Of Medication Inspired Names For Dogs & Other Animals

IDStewardship

In this article a list of medication names for dogs and other animals is provided. Composed By: Timothy P. Gauthier, Pharm.D., BCPS, BCIDP. Article posted 20 August 2022. Recently @HaPhanPharmD asked the twitterverse for good medication names for dogs. Many people commented, sharing some actual names of their pets (see below) or hypothetical names that would be a possible name for a dog (or pair of dogs).

130
130
article thumbnail

COVID-19 Incubation Period Varies by SARS-CoV-2 Strain

Drug Topics

With the evolution of different COVID-19 variants, finding the mean incubation period has become more complex.

281
281
article thumbnail

Flipping the script to disrupt, redefine and accelerate the patient care journey

PharmaVoice

A new, digitally innovative care model empowers patients and expedites their access to treatment.

article thumbnail

Trial Results Suggest Metformin Is Effective at Reducing Odds of Serious COVID-19 Outcomes

Pharmacy Times

University of Minnesota Medical School Analysis shows comparison with fluvoxamine and ivermectin in a double-blinded, placebo-controlled, randomized study.

article thumbnail

Non-viral CRISPR could overcome cell and gene therapy bottlenecks

European Pharmaceutical Review

Scientists from the Gladstone Institutes and University of California San Francisco (UCSF) say a new variation of the CRISPR-Cas9 gene editing system enables especially long DNA sequences to be introduced to precise locations in the genomes of cells with remarkably high efficiency without the need for viral vectors. “One of our goals for many years has been to put lengthy DNA instructions into a targeted site in the genome in a way that doesn’t depend on viral vectors,” commented Alex Marson, MD

article thumbnail

Looking at the CAR-T Therapy Landscape

Drug Topics

More of these treatments have been approved, but supply chain issues and cost remain obstacles.

247
247
article thumbnail

Woman of the Week: Glympse Bio’s Dr. Tram Tran

PharmaVoice

How the chief medical officer of the emerging diagnostic company is using the patient perspective as a guiding light.

147
147
article thumbnail

Expert: Mark Cuban’s Pharmacy Has Shown ‘There’s No Silver Bullet’ to Disrupt the Pharmacy Value Chain

Pharmacy Times

Yoona Kim, PharmD, PhD, co-founder and CEO of Arine, discusses some of the key takeaways from the launch of Mark Cuban's pharmacy Mark Cuban Cost Plus Drug Co.

132
132
article thumbnail

Sword’s digital musculoskeletal care approach improves mental health; study

pharmaphorum

A clinical trial has found that a digital care programme for people with musculoskeletal pain developed by Sword Health can improve their productivity at work, even if they also have mental health issues. Sword Health’s virtual musculoskeletal programme care programme pairs patients with a physical therapist they can talk with via telehealth, guiding them through exercises to address pain and other symptoms and also provides cognitive behavioural therapy (CBT) modules to help them develop

119
119
article thumbnail

Reducing Anxiety in Children with ADHD Using Atomoxetine

Drug Topics

A recent review suggests that atomoxetine can reduce symptoms of anxiety in children and adolescents with ADHD.

247
247
article thumbnail

Moderna, Eli Lilly and Schrödinger seek to boost financial and people strategies with key new hires

PharmaVoice

How the latest personnel shifts are impacting each company and the industry at large.

130
130
article thumbnail

COVID-19 Vaccine Booster Dose Reduces Infection, Hospitalization, Death from Virus in Long-Term Care Facilities

Pharmacy Times

During the surge caused by the Delta variant, a third dose of the Pfizer-BioNTech COVID-19 vaccine reduced infections and COVID-19-related hospitalizations and deaths among patients in long term care facilities.

article thumbnail

Gilead’s Sunlenca receives EC approval to treat HIV

Pharmaceutical Technology

Gilead Sciences has obtained the European Commission (EC) marketing authorisation for Sunlenca (lenacapavir) injection and tablets to treat human immunodeficiency virus (HIV) infection. The twice-yearly treatment is indicated to be administered along with other antiretroviral(s) in adult patients with multi-drug resistant HIV infection who otherwise cannot have a suppressive anti-viral regimen.

FDA 119
article thumbnail

News Roundup: August 22 to August 26

Drug Topics

Your weekly roundup of the latest news from Drug Topics®.

190
190
article thumbnail

Merck chases Bayer/Ionis with fast track for Factor XI drug

pharmaphorum

The FDA has given a novel anticoagulant from Merck & Co a fast-track designation as a treatment for people with end-stage renal disease (ESRD) who need dialysis, firing a warning short over the bows of a rival programme in development at Ionis and Bayer. The anticoagulant – codenamed MK-2060 – is a monoclonal antibody designed to inhibit Factor XI and is currently in a phase 2b trial in ESRD patients on dialysis, who often need to be treated with anticoagulants to prevent blood clots.

FDA 115